Table 1.
Frequency distribution of demographic, multimodal neuromonitoring, and treatment variables with univariate and multivariate analysis results of predictors for the need of retreatment.
| Parameter | Frequency, n (%) | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | ||
| Age > 53 (mean) | 16 (48.5%) | 1.688 (0.414–6.878) | 0.47 | – | – |
| Female sex | 22 (66.7%) | 1.600 (0.369–6.946) | 0.53 | – | – |
| Body mass index > 25 (mean) | 17 (51.5%) | 1.004 (0.983–1.025) | 0.72 | – | – |
| Arterial hypertension | 12 (36.4%) | 1.750 (0.376–8.140) | 0.48 | – | – |
| Smoking | 11 (33.3%) | 0.530 (0.116–2.422) | 0.41 | – | – |
| Hunt and Hess grade 4–5 | 6 (18.2%) | 0.857 (0.145–5.064) | 0.87 | – | – |
| Modified Fisher grade 3–4 | 22 (66.7%) | 1.600 (0.369–6.946) | 0.53 | – | – |
| Intracerebral hemorrhage | 10 (30.3%) | 0.556 (0.122–2.536) | 0.45 | – | – |
| Intraventricular hemorrhage | 18 (54.6%) | 3.667 (0.849–15.844) | 0.08 | – | – |
| Anterior aneurysm location | 28 (84.9%) | 1.875 (0.268–13.094) | 0.53 | – | – |
| Aneurysm occlusion with clipping | 16 (48.5%) | 0.889 (0.216–3.662) | 0.87 | – | – |
| LACTATE/PYRUVATE RATIO | |||||
| >30 | 16 (69.6%) | 1.333 (0.176–10.120) | 0.78 | – | – |
| >40 | 10 (43.8%) | 3.000 (0.525–17.159) | 0.22 | – | – |
| >41 (mean) | 7 (30.4%) | 7.500 (1.039–54.116) | 0.05 | – | – |
| ptiO2 | |||||
| < 5 mmHg | 10 (25.6%) | 31.500 (3.299–300.790) | 0.003* | 32.664 (2.563–416.327) | 0.007* |
| < 10 mmHg | 17 (43.6%) | 2.625 (0.681–10.123) | 0.16 | – | – |
| < 15 mmHg (mean) | 21 (53.9%) | 1.250 (0.330–4.731) | 0.74 | – | – |
| TCD | |||||
| >120 cm/s | 16 (59.3%) | 0.500 (0.102–2.460) | 0.39 | – | – |
| >139 cm/s (mean) | 16 (59.3%) | 0.500 (0.102–2.460) | 0.39 | – | – |
| >150 cm/s | 13 (48.2%) | 0.750 (0.159–3.532) | 0.72 | – | – |
| >180 cm/s | 7 (25.9%) | 0.545 (0.095–3.146) | 0.50 | – | – |
| Generalized CVS | 25 (46.3%) | 4.922 (1.508–16.065) | 0.008** | – | – |
| I.A. NIMODIPINE | |||||
| Dose >19 μg/kg/h (mean) | 19 (46.3%) | 2.500 (0.682–9.164) | 0.17 | – | – |
| Coerced dose reduction | 17 (42.5%) | 1.969 (0.542–7.145) | 0.30 | – | – |
| Discontinuation < 72 h | 13 (31.7%) | 5.630 (1.200–26.414) | 0.03* | 7.973 (0.766–83.046) | 0.08 |
*
Statistically significant result.
**
Omitted from multivariate analysis due to association with ptiO2 < 5 mmHg.
OR, odds ratio; CI, confidence interval; TCD, transcranial doppler; CVS, cerebral vasospasm; i.a., intraarterial.